AbbVie acquires Syndesi Therapeutics, strengthening neuroscience portfolio
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The product will be manufactured at Lupin’s facility in Pithampur, India
Company expects strong organic growth in sales, EBITDA in 2022
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
Subscribe To Our Newsletter & Stay Updated